Hormone replacement therapy (HRT) with estrogen alleviates menopausal symptoms and is effective in reducing osteoporosis and cardiovascular disease when taken in early postmenopause. Older, late postmenopausal women who never previously received HRT are also believed to benefit from estrogen treatment. On the other hand, increased lifetime exposure of the mammary gland to estrogen may increase the risk of breast cancer. The development of suitable experimental animal model systems can advance our understanding of the effects of estrogen and the timing of HRT on the postmenopausal breast. Toward this end, early and late postmenopausal states were induced in mice by short vs. long term ovariectomy (1 vs. 5 weeks), and the effects of 17␤-estradiol (E) on mammary gland morphology, cell proliferation, and progesterone receptor (PR) levels were investigated. We report that in late postmenopausal mice, E caused a pronounced enlargement of duct ends and 6.5-and 4-fold greater mitogenic responses in the duct end epithelium and adjacent stromal cells, respectively, compared with the response in early postmenopausal mice. Furthermore, after long term, daily treatment with E, steady state levels of proliferation remained 2-fold higher than those of similarly treated, early postmenopausal mice. E failed to increase mammary PR levels in late postmenopausal, but not in early postmenopausal mice. Stimulation of duct ends by E and lack of PR inducibility are characteristics of the immature pubertal mammary gland and indicate that the late postmenopausal mammary gland resembled the immature state. In contrast, minimal E-induced proliferation and increased PR inducibility, characteristics of the adult, sexually mature mammary gland, were retained in early postmenopausal mice. The lack of difference in the numbers of estrogen receptor-positive epithelial or stromal cells or in estrogen receptor cellular concentration after short vs. long term ovariectomy indicates that the observed greater efficacy of E is mediated at a step beyond receptor-ligand binding. This mouse model of experimentally induced early vs. late postmenopausal states should prove useful in better understanding alterations in hormone responsiveness and their implications for timing of HRT on the human breast. (Endocrinology
H ORMONE replacement therapy (HRT) with estrogen in postmenopausal women is used to alleviate menopausal symptoms such as vasomotor and urogenital dysfunction as well as to reduce the risk of bone fractures and cardiovascular disease, and it may also decrease the debilitating symptoms of Alzheimer's disease (1) (2) (3) (4) (5) (6) (7) . Although most breast cancers occur in postmenopausal women, the role of menopause per se in the etiology of breast cancer is not known. However, there is solid epidemiological evidence for an important role of ovarian hormones in mammary cancer development (8) . Lifetime total exposure of the mammary gland to the mitogenic effects of ovarian hormones has been proposed to be a major risk factor for the development of breast cancer (8) . However, very little is known about the mitogenic effects of estrogen in the postmenopausal human breast. We have developed a mouse model to study the hormone responsiveness of the postmenopausal mammary gland. The mouse has been widely studied in vivo for elucidating roles of hormones in mammary gland development and function, and the mouse mammary gland is similar to the human breast in many aspects of hormonal regulation of cell proliferation (9) . Most mammals, including mice, maintain their reproductive capacity throughout their entire life and do not experience natural menopause (10) . However, a menopausal state in animals can be induced surgically by ovariectomy (OVX). This is comparable to the situation in women who undergo bilateral OVX before menopause and prematurely experience the symptoms and side-effects of menopause soon after surgery. In many instances women start HRT in the early postmenopausal period to alleviate menopausal symptoms. However, older postmenopausal women who have never previously received HRT are also given estrogen for its ability to reduce osteoporosis and decrease the risk of cardiovascular disease (11) (12) (13) (14) . Thus, it was of interest to study the effects of estrogen in early vs. late postmenopause. To accomplish this, we have investigated the effects of estrogen treatment in mice after either short or long term OVX to approximate early vs. late postmenopausal states, respectively. We report the novel finding of an increased proliferative response of normal mammary epithelial cells to estrogen as a consequence of long term OVX. These findings may have important implications for the timing of HRT in women. 
Materials and Methods Chemicals

Animals, surgical procedures, and hormone administration
Ten-week-old or 9-to 12-month-old BALB/c female mice from our own colony were bilaterally OVX under Nembutal anesthesia 1 or 5 weeks before E treatment. Varying doses of E in 0.85% NaCl were administered by ip or sc injection; in pilot studies results were not significantly different for the two injection routes. Injection was chosen as the method of systemic administration to optimize the precision and reproducibility of hormone dosage. Serum levels of E were determined after OVX and E injection by RIA using a commercial kit (Diagnostic Products, Los Angeles, CA) according to the supplier's instructions. Time-course studies revealed that after E injection, maximal DNA synthesis and morphological responses were observed at 72 and 96 h, respectively. Therefore, in all experiments except time-course studies, mammary glands were analyzed at 72 h after E treatment for DNA histoautoradiography and at 96 h after E treatment for morphological analysis.
DNA histoautoradiography
At various times after E injection, animals received a single ip injection of [ 3 H]thymidine in a dosage of 2 Ci/g BW 1 h before death. The mammary glands were removed, fixed, and processed as wholemounts, followed by embedding and sectioning for histoautoradiographic analysis as described previously (15) . Histological sections were examined at ϫ400 magnification to determine the DNA labeling indexes (LIs) of epithelial and stromal cells. In view of the stimulatory effect of E on duct ends, epithelial cell LIs were also quantitated separately in ducts vs. duct ends. In parallel, stromal cell LIs were determined for areas adjacent to and distal from duct ends. Adjacent areas were defined to be within 400 m of the duct end (i.e. in the same microscope field at ϫ400 magnification), and the distal areas were defined to be more than 400 m away from the duct end. A minimum of 10 individual structures were evaluated for each of 5-9 mice/experimental group. Determination of LI was facilitated by the use of a computer-interfaced morphometric digitizing system as described previously (15) .
Steroid hormone binding assay
To determine the progesterone receptor (PR) concentration, cytoplasmic extracts were prepared separately for mammary gland and uteri as described previously (16) . Mammary gland and uterine cytoplasmic extracts were incubated with a single saturating concentration of 20 nm [ 3 H]R5020 with a 100-fold excess of radioinert dexamethasone (for suppression of progestin binding to glucocorticoid receptors) or with a 100-fold excess of radioinert R5020. Specific binding was determined using a dextran-coated charcoal assay procedure as previously described (16) . Tissue DNA was quantitated as previously described (17) .
Estrogen receptor (ER) immunohistochemistry
The immunohistochemical procedure was carried out on frozen sections of mammary tissue using anti-ER monoclonal antibody, H222 (10 g/ml; gift from Abbott Laboratories, Abbott Park, IL), and was used as described previously (18) . To quantitate the number of ER-positive cells by light microscopy, 3,3Ј-diaminobenzidine tetrahydrochloride chromogen substrate was used, and quantitation of the percentage of ER-positive cells was facilitated by the use of a computer-interfaced morphometric digitizing system (18) . To quantify the amount of ER per cell, the same immunohistochemical procedure was carried out as described above, except that ER antibody was visualized in tissue sections after incubation with a fluorescein-conjugated, goat antirat (1:36 dilution; 45 min at 20 C) secondary antibody (Cappel Research Products, Durham, NC). Fluorescently labeled sections were mounted onto slides with Slow Fade (Molecular Probes, Inc., Eugene, OR) and analyzed under an Odyssey Laser Scanning Confocal Microscope (Noran Instruments, Inc., Madison, WI). The confocal microscope was equipped with Image-1 Software (Universal Imaging Corp., Media, PA), which allows the image storage and fluorescence intensity measurements as described previously (19) . For fluorescein, the excitation and primary barrier filters were 488 and 515 nm, respectively. A ϫ40 objective was used for capturing images, and the binding of anti-ER antibody was quantified using the function Brightness Measurement: Area Brightness of the Image-1. The amount of ER in antibody-treated sections was determined by quantitating the intensity of fluorescence staining. To determine the intensity of fluorescence staining, individual cells were outlined using the Area Brightness function, and the average pixel brightness within the circumscribed areas that was due to anti-ER antibody staining was calculated by the Image-1 program. For anti-ER staining, the background level of fluorescence obtained with normal serum in parallel control sections was subtracted from fluorescence intensity obtained with anti-ER antibody. In all cases images were captured and stored by 24 h after antibody treatment to reduce variability due to fluorescence fading. There were no significant differences in fluorescence measurements between sections from the same treatment groups.
Statistical analysis
All data are expressed as the mean Ϯ sem and were analyzed for significance using Student's t test or ANOVA as appropriate. P Յ 0.05 was chosen for significance.
Results
Effect of time after OVX and age on E responsiveness
In adult mice, endogenous serum E reaches baseline levels by 24 -48 h post-OVX (20) . The shortest period of time previously used for the mammary gland to achieve a baseline against which responses to exogenously administered E could be measured and for mice to recover from surgery was 1 week post-OVX (15, 16, 18, 19) . Thus, 1 week post-OVX was selected as an experimental approximation of an early postmenopausal state. To analyze the mammary gland response in a simulated early vs. late postmenopausal state, the morphological response to E treatment of adult mice was assessed at varying times post-OVX. Fig. 1a shows that the percentage of mammary glands exhibiting a morphological response after E treatment increased with increasing length of time after OVX, with 100% of the glands exhibiting stimulation of duct ends in animals at 5 weeks post-OVX. In control injected mice 1 and 5 weeks post-OVX, mammary gland morphology was identical and was characterized by simple ducts lacking significant side-branching and alveolar buds (Fig. 2, c and d ). E treatment at 1 week post-OVX had no effect on morphology (Fig. 2a) . However, E treatment at 5 weeks post-OVX produced enlarged duct ends (Fig. 2b) . Histological analysis of the enlarged duct ends revealed the presence of multiple layers of epithelial cells (Fig. 3a) . These enlarged duct ends were similar in appearance to end buds growing in response to endogenous E in mammary glands of ovary-intact, immature pubertal mice (Fig. 3c) . End buds are the epithelial structures that exhibit the highest degree of proliferation and are major growth points leading to ductal elongation during puberty. Estrogen withdrawal by OVX in both immature and adult mice produced quiescent duct ends characterized by a single layer of epithelial cells and a reduced number of DNA synthetic cells (Fig. 3, b and d) .
Menopause results in the loss of ovarian function in hu-mans, but also occurs with advanced age, with a mean age at menopause of 50 yr (21) . The average life span of the laboratory mouse is about 2 yr; thus, 12 months is roughly equivalent to middle age in the mouse. To include the age component in reproducing a postmenopausal status in mice, 9-to 12-month-old animals were also OVX at 1, 3, or 5 weeks before E treatment. As shown in Fig. 1b , the extent of the stimulatory response to E as a function of time after OVX was identical to that obtained in 10-week-old mice. Furthermore, the morphological response was also identical (data not shown). Because length of time after OVX rather than age was the major determining factor of the extent of the E response, in the interest of reducing the time and cost required for these studies, all further experiments were carried out using 10-week-old mice. Mice OVX 1 or 5 weeks before E treatment were chosen to represent early and late postmenopausal states, respectively, in this study. Sex steroid hormones are also produced by the adrenal glands. One possible explanation for the enhanced response to E observed with increasing time after OVX was a compensatory increase in circulating E derived from adrenal gland biosynthesis. This did not appear to be a likely explanation based upon the persistent attenuated ductal morphology observed at 5 weeks post-OVX. However, to address the question of adrenal hormone contribution directly, the study was repeated in mice that were OVX as well as adrenalectomized. The morphological and DNA synthesis results obtained were identical to those obtained with OVX alone (data not shown), ruling out a significant adrenal contribution to the E response observed at 5 weeks post-OVX.
Time course and dose response of E-induced cell proliferation
A time-course study revealed that the maximal proliferative response in mammary epithelial cells and stromal cells occurred at 72 h after E injection (Fig. 4) . To determine whether the enhanced proliferative response to E at 5 weeks post-OVX was due to an increase in E potency or to an increase in E efficacy, a dose-response study was carried out (Fig. 5) . The maximum proliferative response observed at 5 weeks post-OVX was 5.6-and 2.5-fold greater than that at 1 week post-OVX for epithelial cells and stromal cells, respectively. The ED 50 values at 1 and 5 weeks post-OVX were identical, indicating that the potency of E was the same in the two groups. By contrast, the response to E was significantly greater at 5 weeks post-OVX than at 1 week post-OVX. Thus, these results indicate that the increase in E-induced proliferation observed at 5 weeks post-OVX was due to an increase in E efficacy rather than potency. At 1 and 5 weeks post-OVX basal serum levels of E were 5.4 Ϯ 0.7 (n ϭ 7) and 5.4 Ϯ 0.5 (n ϭ 8) pg/ml, respectively. Injection of 1 g E at 5 weeks post-OVX resulted in a serum E level of 31 Ϯ 7.8 pg/ml (n ϭ 4) at 24 h after injection. This was similar to that in ovaryintact mice (25 pg/ml on day 1 of the estrous cycle) (20) . Thus, in the interest of using a physiological dose of E, all subsequent studies were conducted using 1 g E.
Topographical analysis of E-induced proliferation in relation to specific mammary gland structures
Because E treatment produced a pronounced stimulation in the duct ends at 5 weeks post-OVX, it was of interest to obtain a better understanding of the proliferative effects of E on specific mammary gland structures. To accomplish this, LIs were determined individually for duct ends vs. subtending ducts. In parallel, stromal cell LIs were determined for cells adjacent to vs. distal from duct ends. When LIs were analyzed in this way (Fig. 6 ), there was a 6.5-fold higher E-induced stimulation of DNA synthesis in duct ends at 5 weeks post-OVX than at 1 week post-OVX. Furthermore, little or no DNA synthesis was observed in ducts. Analysis of stromal cell LIs (Fig. 7 ) revealed a 4-fold higher stimulation of DNA synthesis in the stromal cells immediately surrounding the enlarged duct ends at 5 weeks post-OVX vs. that in stroma adjacent to the quiescent duct ends at 1 week post-OVX. These results indicate that there is a paracrine interaction between proliferating duct end epithelium and nearby stroma that occurs only over a short distance.
ER levels
The increased efficacy of E could be due to an increase in ER concentration; therefore, the ER content of the mammary FIG. 1. Effect of time after OVX on E-induced changes in mammary gland morphology in 10-week-old and 9-to 12-month-old mice. Tenweek-old (A) or 9-to 12-month-old (B) mice were OVX for the indicated lengths of time before a single ip injection of 1 g estradiol (E) or 0.85% NaCl vehicle control (C). Four days later, the mammary glands were prepared as wholemounts and analyzed for changes in morphology. Each bar represents the percentage of mammary glands that exhibited enlarged duct ends, with eight mice per time point, for each age group.
glands was analyzed. As estrogen is believed to stimulate mammary epithelial proliferation indirectly via a paracrine mechanism as the result of estrogen action on nearby ERpositive mammary stromal cells (22, 23) , ER content was determined separately for the epithelial and stromal cell compartments by immunohistochemical analysis. Figure 8a shows that there was no difference in the percentage of ER-positive epithelial cells in control mice at 1 and 5 weeks post-OVX. Similarly, there was no significant difference in the percentage of ER-positive stromal cells in control mice at 1 and 5 weeks post-OVX (Fig. 8b) . However, the percentage of ER-positive stromal cells was only about 50% that of ERpositive epithelial cells. Because of the proposed role of stromal cells to mediate E-induced epithelial proliferation, we also quantitated the percentages of ER-positive stromal cells, either adjacent to or distant from duct ends, at 1 and 5 weeks post-OVX. ER-positive stromal cells were evenly distributed throughout the mammary gland, and no significant differences were observed between the 1 and 5 weeks post-OVX groups in either control or E-injected mice (data not shown). At 24 h after E injection, the percentages of ER-positive epithelial and stromal cells were significantly decreased at both 1 and 5 weeks post-OVX, indicative of ER down-regulation by E.
Although the percentages of ER-positive epithelial or stromal cells were not significantly different at 1 vs. 5 weeks post-OVX, it was possible that the ER concentration per cell was different between the two groups. To address this question, immunohistochemical analysis of ER was carried out using a fluorescein-conjugated secondary antibody detection system. This allowed the quantitation of fluorescence intensity as a measure of ER concentration per cell. Analysis of ER cellular content by this method showed no differences at 1 vs. 5 weeks post-OVX in either epithelial or stromal cells (Fig. 9,  a and b) . Decreased cellular ER content was also observed in both epithelial and stromal cells after E treatment.
Estrogenic regulation of PR levels
Another end point of estrogen action in the adult mammary gland is increased epithelial cell PR levels (16) . Because long term OVX conferred an increased proliferative response to E, it was of interest to determine whether E treatment produced a similar enhanced effect on PR regulation. When specific [ 3 H]R5020 binding was measured at 24 h after E injection, a 2.5-fold increase in PR binding was obtained at 1 week post-OVX (Fig. 10) . In contrast, no significant increase in PR binding was observed at 5 weeks post-OVX. To de- termine whether the lack of increase in PR was due an altered time course of PR induction at 5 weeks post-OVX, PR levels were measured at 12, 24, and 36 h after E injection (Fig. 11a) . No increase in PR was observed at 5 weeks post-OVX over the entire period tested. The lack of PR induction in mammary glands was not due to an overall lack of E responsiveness at 5 weeks post-OVX, as an 8-fold increase in PR was observed in the uteri of the same mice 24 h after injection (Fig. 11b) .
Effects of long term E treatment
Because women often take HRT for long periods of time, it was of interest to analyze the proliferative response of the mammary glands starting at 1 and 5 weeks post-OVX to long term, continuous treatment with E. To accomplish this, E or saline was injected sc daily for up to 28 days. As shown in Fig. 12a , the maximal proliferative response in the epithelial cells at 5 weeks post-OVX was observed after 3 days of E injection and was 2.6-fold higher than that at 1 week post-OVX. The epithelial cell proliferative response decreased to a steady state level of proliferation but remained 2.3-fold higher than that started at 1 week post-OVX. After 3 days of E injection at 5 weeks post-OVX, the mammary gland contained enlarged duct ends similar to those observed at 96 h after a single E injection. As a steady state LI was reached at 11-14 days, the duct ends remained enlarged, but contained fewer [
3 H]thymidine-labeled cells (data not shown). A similar pattern of increased proliferative response to E was seen in mammary stromal cells at 5 weeks post-OVX. The increased steady state proliferative response to E in both mammary epithelial and stromal cells when continuous, long term E treatment was started at 5 weeks post-OVX indicates that long term OVX confers a permanent alteration in mammary gland responsiveness to E.
Discussion
In this paper we have examined the effects of E treatment at an early time (1 week) vs. those at a late time (5 week) post-OVX on mammary gland morphology, cell proliferation, and PR regulation. We view this study as a model for understanding the effects of HRT with E in an early vs. late postmenopausal mammary gland. The novel findings from our studies demonstrate that a postmenopausal state produced by long term OVX conferred an enhanced proliferative response to E, which was characterized morphologically by a pronounced hyperplasia of duct ends. This increased mitogenic response to E was localized to the epithelium of these duct ends and nearby stromal cells and resulted in 6.5-and 4-fold increased LI in this epithelium and stroma, respectively. Long term E treatment produced a lower steady state proliferative response. However, both epithelial and stromal cell proliferations were 2-fold higher when long term E treatment was started at 5 weeks post-OVX vs. 1 week post-OVX. Thus, there was an apparent permanent enhanced proliferative response to E after long term OVX. By contrast, no morphological response and minimal epithelial and stromal cell proliferation were observed after any length of E treatment in short term OVX, early postmenopausal mice. Anal- ysis of age vs. length of time after OVX on the mammary gland response revealed that the enhanced proliferative response was determined by length of time after OVX.
The time points 1 and 5 weeks post-OVX appear to be appropriate choices to represent early and late postmenopausal states, respectively. Our results show that 1 week post-OVX is the shortest period of time required by the adult mammary gland to achieve a baseline against which a response to exogenously administered E can be measured. Although serum levels are reduced to baseline in adult mice 2-3 days after OVX (20) , our data in Fig. 4 show that after a single injection of 1 g E, cell proliferation was not reduced to a baseline level by 4 days. However, by 1 week post-OVX, basal levels of proliferation were reached for both mammary epithelium and stroma and were not further decreased with increasing time up to 5 weeks post-OVX (Fig. 4) . Furthermore, morphological and histological evidence demonstrate that the mammary glands of 1 week OVX mice were regressed compared with those in the ovary-intact state. Thus, the period of 1 week post-OVX is a reasonable time point to choose for the early postmenopausal state. We have since carried out studies in mice at 10 and 15 weeks post-OVX and have observed estrogenic stimulation of duct ends at these time points (Raafat, A. M., and S. Z. Haslam, unpublished observations). Thus, 5 weeks post-OVX appears to be an appropriate time point for the late postmenopausal state and exhibits the responses to E that are also observed at much longer times post-OVX.
The enlarged duct ends obtained in response to E in long term OVX mice were similar in histological appearance to end buds of immature pubertal mice. End buds are the epithelial structures that exhibit the highest degree of proliferation and are major growth points leading to ductal morphogenesis during puberty. Analysis of E regulation of PR revealed that there is also a lack of PR inducibility at 5 weeks 3 H]thymidine was injected ip, and mammary glands were removed 1 h later and processed for DNA histoautoradiography as described in Materials and Methods. LIs for epithelial (A) and stromal (B) cells were determined. Each bar represents the mean Ϯ SEM of values obtained from five or six mice per time point in each experimental group. As the LIs never exceeded 0.05% at any time point for both the 1 and 5 week OVX control groups, the LIs for control injected mice have been combined for all time points for each experimental group. *, P ϭ 0.05, LIs of E-injected glands were significantly greater than LIs of control injected glands. **, P ϭ 0.01, LIs of E-treated glands were significantly greater at 5 weeks post-OVX than at 1 week post-OVX. 3 H]thymidine was injected ip, and mammary glands were removed 1 h later and processed for DNA histoautoradiography as described in Materials and Methods. LIs for epithelial (A) and stromal (B) cells were determined. Each bar represents the mean Ϯ SEM of values obtained from five or six mice per dose in each experimental group. As the LIs never exceeded 0.05% at any time point for both the 1 and 5 week OVX control groups, the LIs for control mice have been combined for all time points for each experimental group. *, P ϭ 0.05, all E-treated glands had higher LIs than control-treated glands. **, P ϭ 0.01, all E-treated glands at 5 weeks post-OVX had higher LIs than E-treated glands at 1 week post-OVX.
post-OVX. The presence of enlarged duct ends in the form of end buds, and the lack of PR inducibility in response to E treatment are characteristic features of the mammary glands of immature, pubertal mice. The present results indicate that long term OVX can produce these characteristics of the immature gland in adult mice. This observation is of particular interest with regard to mammary gland susceptibility to carcinogenesis, as it is well established that the mammary glands of immature, pubertal mice and rats are the most susceptible to carcinogen-induced mammary tumorigenesis (24) . Thus, it will be of great interest to determine the influence of long vs. short term OVX and E replacement on susceptibility to mammary tumorigenesis.
The results of dose-response studies lead us to conclude that enhanced E responsiveness may be at least in part due to an increased efficacy of E. Recent studies using mammary tissue recombinants in ER knockout mice have provided compelling evidence in the mouse that the proliferative effect of E in epithelial cells is indirect and requires the presence of ER in mammary stroma (22) . In light of these findings, it was important to determine the number of ER-positive cells and cellular ER content separately for the epithelium and stroma. The results of immunohistochemical analysis of mammary gland ER content revealed that the percentages of ER-positive cells and ER cellular content were not significantly different in short vs. long term OVX mice for either epithelial or stromal cells. Thus, increased efficacy of E at 5 weeks post-OVX does not appear to be due to increased ER content in either the epithelial or stromal cell compartments, and this suggests that amplification of the E response occurs at a postreceptor-ligand binding step(s).
In addition to the enhanced mitogenic effect of E on mammary epithelial cell proliferation, the 3-fold increased proliferative response in mammary stromal cells is noteworthy. Interestingly, proliferation of stromal cells occurred mainly in cells that were close to the proliferating epithelium of duct ends. We have previously shown that the local stromal environment has the capacity to influence mammary epithelial cell behavior and, in particular, can enhance epithelial cell response to E, possibly through the production of growth factors (23) . Furthermore, in vitro, under coculture conditions, mammary epithelial cells have been shown to promote E-dependent stromal cell proliferation (25) . Thus, the enhanced sensitivity of mouse mammary gland to E after long term OVX is probably mediated through estrogenic effects in the stroma. Furthermore, our results demonstrate that epithelial-stromal cell interactions may be bidirectional, and epithelial cells may influence the proliferative response of nearby stromal cells.
A dissociation between E stimulation of cell proliferation and PR regulation in the mouse mammary gland has previously been reported (26) . Although E appears to mediate the proliferation of epithelial cells indirectly via stroma, E acts directly in epithelial cells to increase PR levels (27) . Thus, our observations of increased responsiveness to the proliferative effect but decreased responsiveness to the PR regu- ]thymidine was injected ip, and mammary glands were removed 1 h later and processed for DNA histoautoradiography as described in Materials and Methods. LIs were determined separately for ducts vs. duct ends. Each bar represents the mean Ϯ SEM of a minimum of 50 individual structures and a minimum of 2500 cells for each experimental group (n ϭ 5 and 9 mice/group at 1 and 5 weeks post-OVX, respectively). *, P ϭ 0.02-0.001, LI of duct ends in E-injected glands was significantly greater than LIs of all ducts or duct ends in control glands. **, P ϭ 0.001, LI of duct ends in E-treated mice at 5 weeks post-OVX was significantly greater than that in E-treated mice at 1 week post-OVX.
FIG.
7. E-induced proliferation in stromal cells adjacent to or distant from mammary duct ends at 1 or 5 weeks post-OVX. Mice were OVX 5 (A) or 1 (B) weeks before treatment with E by a single ip injection with 1 g E or 0.85% NaCl (C). After 72 h, [ 3 H]thymidine was injected ip, and mammary glands were removed 1 h later and processed for DNA histoautoradiography as described in Materials and Methods. LIs were determined for 50 separate areas that were either adjacent to or distant from (Ͼ400 m away) duct ends. Each bar represents the mean Ϯ SEM of a minimum of 50 separate areas and a minimum of 2500 cells for each experimental group (n ϭ 5 and 9 mice/group at 1 and 5 weeks post-OVX, respectively). *, P ϭ 0.001, E-injected glands had significantly higher LIs than control-treated glands. **, P ϭ 0.001, the LI in stromal cells adjacent to duct ends in E-treated glands was significantly greater at 5 weeks post-OVX than at 1 week post-OVX.
latory effect of E indicate that mammary epithelial and stromal cells are affected differently by long term OVX. To confirm this observation, we have also used immunohistochemical analysis to determine the percentage of PR-positive cells and PR concentration per cell using a fluorescein-conjugated secondary antibody detection system similar to the ER immunofluorescence assay herein. In concordance with the ligand binding assay results we found that the PR concentration per cell increased 2-fold in 1 week post-OVX Etreated mammary glands, but there was no significant increase in either the number of PR-positive cells or the amount of PR per cell in the 5 week post-OVX E-treated glands (Raafat, A. M., and S. Z. Haslam, unpublished observations). Future studies are planned to determine the mechanistic basis of these different responses to OVX. A similar dissociation of estrogenic regulation of proliferation and PR level has recently been reported for normal human breast (28) . It has been proposed that E acts indirectly to stimulate the proliferation of normal human breast epithelium, as ER and markers of cell proliferation do not colocalize in the same epithelial cells. In contrast, as ER and PR do colocalize in the same cells, E appears to act directly to regulate PR in breast epithelial cells. These additional similarities between the human and mouse mammary glands increase the attractiveness of the mouse model to study the hormonal responsiveness of the postmenopausal breast.
Heightened sensitivity to the mitogenic effects of estrogen after withdrawal from estrogen has been previously reported to occur in the MCF-7 human breast carcinoma cell line (29) . A shift in the dose for maximal proliferative response to estradiol from 10 Ϫ10 to 10 Ϫ14 m was observed in cell culture when MCF-7 cells were deprived of estrogen for 1-6 months. Although there was a 4-fold increase in the ER concentration, the researchers concluded that this alone could not account for the increased sensitivity to E; no differences in receptor ligand binding affinity were observed in these studies. The enhanced sensitivity to the mitogenic effect of E was also observed in vivo. Nude mice implanted with the E-deprived cells demonstrated an earlier appearance of palpable tumors in response to E than animals bearing wild-type cells. Al- .85% NaCl (C). After 24 h, mammary glands were removed and processed for ER by immunohistochemistry using a fluorescein-conjugated secondary antibody for the detection system. ER was quantitated in mammary epithelium (A) and stroma (B) as described in Materials and Methods. Each bar represents the mean Ϯ SEM of a minimum of 6000 cells for each experimental group (n ϭ 6 mice for each treatment group).
though no specific mechanism(s) has been identified to explain the increased E sensitivity in E-deprived MCF-7 cells, it does not appear to be the same as the enhanced proliferative response obtained herein after long term OVX. In the case of MCF-7 cells, a shift in the dose-response curve was observed that rendered the E-deprived cells maximally responsive to lower doses of E. In contrast, in the present study, a maximal proliferative response was obtained at the same E dose in long and short term OVX mice. However, the extent of the response was higher in the duct ends of long term OVX mice. Furthermore, no significant difference in ER content between the two groups was observed herein.
We have also examined the proliferative response to E in our model after implanting small doses of E into the mammary gland to assess the direct effect of E on the mammary gland vs. E-induced systemic factors, such as hormones or growth factors/growth inhibitors produced elsewhere in the body (30 -34) . Interestingly, the results obtained with systemically administered E herein, were virtually identical to those obtained with E implants with regard to the enhanced proliferation, the histological and morphological characteristics of the response, and the lack of PR inducibility (Raafat, A. M., and S. Z. Haslam, unpublished observations). This suggests that the major effect of estrogen on mammary cells is direct and not due to systemically induced factors.
To our knowledge, only one other in vivo model, the cynomolgus macaque, has been developed to study the effect of HRT on the postmenopausal mammary gland (35) . In the cynomolgus macaque, a postmenopausal state was surgically induced by long term OVX (2 yr). Long term treatment of postmenopausal monkeys with estrogen for 36 months resulted in increased thickness and percentage of epithelial tissue and increased epithelial cell proliferation (35) . Thus, the results obtained after E treatment in the monkey after long term OVX agree with our findings of increased E-induced epithelial cell proliferation after long term OVX in the mouse.
In women, with the cessation of ovarian function after menopause there is a significant reduction in the mitotic activity of mammary tissue (36) . In a recent report, very low levels of mammary epithelial cell proliferation were reported in breast biopsies obtained from postmenopausal women receiving estrogen HRT (37). Although not specified, it is likely that these samples were obtained from women who initiated estrogen HRT in the early postmenopausal period, as that is the time when the majority of women start HRT. In this regard, the low level of E-induced mammary cell proliferation in short term OVX mice is compatible with the finding of low estrogen-induced breast cell proliferation in women when HRT is initiated in the early postmenopausal period. In the same study, the women receiving estrogen HRT also had elevated PR levels in their breast tissue. Thus, another similarity between the short term OVX, early postmenopausal mouse and the early postmenopausal human breast is increased PR after estrogen treatment.
The increased incidence of breast cancer in postmenopausal women may be simply coincidental with advanced age. Alternatively or in addition, it is possible that there is something specific about the postmenopausal breast that enhances the development of mammary cancer. A significant percentage of postmenopausal breast cancers are hormone responsive and regress in response to antiestrogen therapy (38) . It seems paradoxical that breast cancers that are quite responsive to ovarian hormones arise at a time when ovarian function has ceased, and the influence of these hormones appears to be minimal. One interpretation is that breast cancers may arise from and/or be comprised of cells that are supersensitive to the growth-promoting effects of estrogen. Our present studies in mice suggest that altered hormonal milieu and long term deprivation of ovarian hormones, rather than advanced age may be the major contributing factor to the enhanced sensitivity to E observed in mice and raise the question of whether enhanced sensitivity to estrogen occurs after menopause in the human breast. The current results obtained in mice considered in conjunction with the results of estrogen HRT obtained in the monkey model and in postmenopausal women lead us to propose that the timing of initiation of HRT with estrogen in early postmenopausal vs. late postmenopausal women could have different consequences for the proliferative response of mammary cells to estrogen. These results have added significance because of a potential new pattern of timing of HRT in women. Previously, women started HRT in the early postmenopausal period to alleviate menopausal symptoms. However, with reports that HRT has beneficial effects on bone density and cardiovascular health in older women, late postmenopausal women who never received HRT in early postmenopause are now being prescribed HRT (11) (12) (13) (14) . Our findings of enhanced proliferative response to E with increasing length of time after OVX suggest that the proliferative response of older, late postmenopausal women receiving HRT for the first time may be greater than that of early postmenopausal women. Furthermore, if increased breast cancer risk associated with estrogen HRT in women is due to the mitogenic effect of estrogen in breast tissue, then the timing of HRT could also play a crucial role.
Clearly, hormonal responsiveness of the postmenopausal human breast needs to be investigated more thoroughly to better understand and assess the potential consequences of HRT. An important approach to this problem is the development of suitable experimental animal model systems. We propose that the induction of short vs. long term OVX in mice is one such model system and may provide important information about potential alterations in hormonal responsiveness of the early and late postmenopausal human breast.
12. E-induced proliferation in mammary epithelial and stromal cells during long term treatment at 1 vs. 5 weeks post-OVX. Mice were OVX 1 or 5 weeks before daily sc injection with 1 g E or 0.85% NaCl (C) for 28 days. At 24 h after the indicated number of daily injections, [ 3 H]thymidine was injected ip, and mammary glands were removed 1 h later and processed for DNA histoautoradiography as described in Materials and Methods. Control mice were processed at 28 days. LIs for epithelium (A) and stromal (B) cells were determined. Each bar represents the mean Ϯ SEM of values obtained from one to three separate experiments, with a total of three to nine mice per time point at 1 and 5 weeks post-OVX. A: *, P ϭ 0.01-0.05, LIs for epithelial cells of E-treated mice at 5 weeks post-OVX were greater than those for all control and E-treated mice at 1 week post-OVX. B: *, P ϭ 0.001-0.05, LIs for stromal cells of E-treated mice at 5 weeks post-OVX were greater than those for all control and E-treated mice at 1 week post-OVX.
